Desvenlafaxine Succinate is Used for treating depression, including maintenance treatment of major depressive disorder. It was first introduced by Pf Prism Cv in its drug Pristiq on Feb 29, 2008. 11 different companies have introduced drugs containing Desvenlafaxine Succinate.
Desvenlafaxine Succinate Patents
Given below is the list of patents protecting Desvenlafaxine Succinate, along
with the drug name that holds that patent and the company name owning that
drug.
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Desvenlafaxine Succinate Generic API Manufacturers
Several generic applications have been filed for Desvenlafaxine Succinate. The first generic version for Desvenlafaxine Succinate was by Alembic Pharmaceuticals Ltd and was approved on Jun 29, 2015. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jan 15, 2025.
Given below is the list of companies who have filed for
Desvenlafaxine Succinate generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Actavis Labs Fl.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Jul 29, 2016
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Jul 29, 2016
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Jul 29, 2016
2. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Alembic.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Sep 14, 2018
Manufacturing Plant Locations
New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
Hikma Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Hikma.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Feb 16, 2016
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Feb 16, 2016
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Aug 28, 2017
Manufacturing Plant Locations
New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
Country
City
Firm Name
United States
Eatontown
Hikma Pharmaceuticals USA, Inc.
Cherry Hill
Hikma Pharmaceuticals USA Inc.
Carlsbad
Hikma Cali Inc. DBA Leucadia Pharmaceuticals
Dayton
Hikma Injectables USA Inc
Portugal
Terrugem Snt
Hikma Farmaceutica, (Portugal) S.A.
Jordan
Amman
Hikma Pharmaceuticals LLC
4. LUPIN LTD
Lupin Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Lupin Ltd.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Apr 13, 2022
Manufacturing Plant Locations
New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
Country
City
Firm Name
India
Aurangabad
Lupin Ltd.
5. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Macleods Pharms Ltd.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Jan 15, 2025
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Jan 15, 2025
6. MEDICAP LABS
Medicap Laboratories has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Medicap Labs.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
May 7, 2019
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
May 7, 2019
7. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Norvium Bioscience.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 100MG BASE
tablet, extended release
Discontinued
ORAL
N/A
Jun 29, 2015
EQ 50MG BASE
tablet, extended release
Discontinued
ORAL
N/A
Jun 29, 2015
8. RUBICON
Rubicon Research Private Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Rubicon.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Jun 29, 2015
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Dec 7, 2023
Manufacturing Plant Locations
New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
Country
City
Firm Name
United States
Geismar
Rubicon, LLC
Indianapolis
Rubicon Foods LLC
Canada
Concord
Rubicon Research Canada Limited
India
Ambarnath
Rubicon Research Private Limited
9. YICHANG HUMANWELL
Yichang Humanwell Pharmaceutical Co Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Yichang Humanwell.
Strength
Dosage Form
Availability
Application Pathway
TE code
Launch Date
EQ 100MG BASE
tablet, extended release
Prescription
ORAL
AB
Oct 1, 2018
EQ 50MG BASE
tablet, extended release
Prescription
ORAL
AB
Oct 1, 2018
EQ 25MG BASE
tablet, extended release
Prescription
ORAL
AB
Oct 13, 2020
Manufacturing Plant Locations
New
Yichang Humanwell's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Yichang Humanwell as present at those locations.
Country
City
Firm Name
China
Yichang
Yichang Humanwell Oral Solid Dosage Plant
10. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the
details of the strengths of this generic introduced by
Zydus Pharms.
